Loading...

Zentalis Pharmaceuticals ($ZNTL)

Stock Image

ZNTL Overview

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States.Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer.The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York. (From: StockAnalysis.com)

MORE ABOUT Zentalis Pharmaceuticals

Stay up to date with the best of Bullish each week.

BULLISH WEEKLY

Stay up to date with the best of Bullish each week.